This review discusses the biosimilars, their regulation globally and their difference from generics from ophthalmic perspective.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: